Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56


Chemopreventive effects of atractylenolide II on mammary tumorigenesis via activating Nrf2-ARE pathway.

Wang T, Long F, Zhang X, Yang Y, Jiang X, Wang L.

Oncotarget. 2017 Aug 24;8(44):77500-77514. doi: 10.18632/oncotarget.20546. eCollection 2017 Sep 29.


Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation.

Quirke VM.

Front Pharmacol. 2017 Sep 12;8:620. doi: 10.3389/fphar.2017.00620. eCollection 2017.


Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).

Smith SG, Sestak I, Howell A, Forbes J, Cuzick J.

J Clin Oncol. 2017 Aug 10;35(23):2666-2673. doi: 10.1200/JCO.2016.71.7439. Epub 2017 Jun 29.


Physician and Patient Barriers to Breast Cancer Preventive Therapy.

Hum S, Wu M, Pruthi S, Heisey R.

Curr Breast Cancer Rep. 2016;8(3):158-164. Epub 2016 Jun 13. Review.


Genomic Biomarkers for Breast Cancer Risk.

Walsh MF, Nathanson KL, Couch FJ, Offit K.

Adv Exp Med Biol. 2016;882:1-32. doi: 10.1007/978-3-319-22909-6_1. Review.


Optimal delivery of male breast cancer follow-up care: improving outcomes.

Ferzoco RM, Ruddy KJ.

Breast Cancer (Dove Med Press). 2015 Nov 23;7:371-9. doi: 10.2147/BCTT.S75630. eCollection 2015. Review.


Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.

Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J, Cuzick J.

Ann Oncol. 2016 Apr;27(4):575-90. doi: 10.1093/annonc/mdv590. Epub 2015 Dec 8. Review.


Medical prevention of breast cancer.

Stubert J, Dieterich M, Gerber B.

Breast Care (Basel). 2014 Dec;9(6):391-6. doi: 10.1159/000369573. Review.


Atypical hyperplasia of the breast--risk assessment and management options.

Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K.

N Engl J Med. 2015 Jan 1;372(1):78-89. doi: 10.1056/NEJMsr1407164. No abstract available.


Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators.

Lancet Oncol. 2015 Jan;16(1):67-75. doi: 10.1016/S1470-2045(14)71171-4. Epub 2014 Dec 11.


Risk-benefit profiles of women using tamoxifen for chemoprevention.

Nichols HB, DeRoo LA, Scharf DR, Sandler DP.

J Natl Cancer Inst. 2014 Dec 3;107(1):354. doi: 10.1093/jnci/dju354. Print 2015 Jan.


Preventative therapies for healthy women at high risk of breast cancer.

Sestak I.

Cancer Manag Res. 2014 Oct 17;6:423-30. doi: 10.2147/CMAR.S55219. eCollection 2014. Review.


Main controversies in breast cancer.

Zervoudis S, Iatrakis G, Tomara E, Bothou A, Papadopoulos G, Tsakiris G.

World J Clin Oncol. 2014 Aug 10;5(3):359-73. doi: 10.5306/wjco.v5.i3.359. Review.


The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators.

Craig Jordan V, McDaniel R, Agboke F, Maximov PY.

Steroids. 2014 Nov;90:3-12. doi: 10.1016/j.steroids.2014.06.009. Epub 2014 Jun 17.


Current strategies for the prevention of breast cancer.

Advani P, Moreno-Aspitia A.

Breast Cancer (Dove Med Press). 2014 May 2;6:59-71. doi: 10.2147/BCTT.S39114. eCollection 2014. Review.


Targeted therapy for breast cancer prevention.

den Hollander P, Savage MI, Brown PH.

Front Oncol. 2013 Sep 23;3:250. doi: 10.3389/fonc.2013.00250. Review.


Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL; SERM Chemoprevention of Breast Cancer Overview Group.

Lancet. 2013 May 25;381(9880):1827-34. doi: 10.1016/S0140-6736(13)60140-3. Epub 2013 Apr 30. Review.


Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment.

Taromaru GC, DE Oliveira VM, Silva MA, Montor WR, Bagnoli F, Rinaldi JF, Aoki T.

Oncol Lett. 2012 Mar;3(3):682-688. Epub 2011 Dec 21.


Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.

Waters EA, McNeel TS, Stevens WM, Freedman AN.

Breast Cancer Res Treat. 2012 Jul;134(2):875-80. doi: 10.1007/s10549-012-2089-2. Epub 2012 May 24.

Supplemental Content

Support Center